Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data

At the American College of Cardiology, Lexicon Pharmaceuticals Inc LXRX highlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients.
Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo.
Also See: Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization.
A follow-up analysis of the trial revealed consistent reductions in major adverse cardiovascular events (MACE) in two subgroups —a 21% reduction in MACE in patients with cardiovascular disease and a 26% reduction in MACE in those without CVD.
In February, Lexicon pulled back a submission for approval in Type 2 diabetes patients with heart failure. That came on top of an FDA rejection for sotagliflozin in 2019 in Type 1 diabetes.
Price Action: LXRX shares are up 3.11% at $2.32 during the premarket session on the last check Monday.